Zhong-Lin Zhang1, Zhi-Su Liu, Quan Sun. 1. Department of General Surgery, Zhongnan Hospital, Wuhan University, Wuhan 430071, Hubei Province, China. zhangzhonglin221@sina.com
Abstract
AIM: To investigate the effects of thalidomide on angiogenesis, tumor growth and metastasis of hepatocellular carcinoma in nude mice. METHODS: Twenty-four nude mice were randomly divided into therapy group and control group, 12 mice in each group. Thalidomide dissolved in 0.5% sodium carboxyl methyl cellulose (CMC) suspension was administered intraperitoneally once a day at the dose of 200 mg/kg in therapy group, and an equivalent volume of 0.5% CMC in control group. Mice were sacrificed on the 30th d, tumor size and weight and metastases in liver and lungs were measured. CD34 and VEGF mRNA in tumor tissue were detected by immunohistochemistry and semi-quantitative RT-PCR respectively and microvessel density (MVD) was counted. Serum concentrations of TNF-alpha and ALT and AFP were also tested. RESULTS: MVD and VEGF mRNA in therapy group were less than those in control group (31.08+/-16.23 vessels/HP vs 80.00+/-26.27 vessels/HP, 0.0538+/-0.0165 vs 0.7373+/-0.1297, respectively, P<0.05). No statistical difference was observed in tumor size and weight and metastases in liver and lungs. TNF-alpha was significantly lower in therapy group than in control group (28.64+/-4.64 ng/L vs 42.69+/-6.99 ng/L, P<0.05). No statistical difference in ALT and AFP was observed between groups. CONCLUSION: Thalidomide can significantly inhibit angiogenesis and metastasis of hepatocellular carcinoma. It also has inhibitory effects on circulating TNF-alpha.
AIM: To investigate the effects of thalidomide on angiogenesis, tumor growth and metastasis of hepatocellular carcinoma in nude mice. METHODS: Twenty-four nude mice were randomly divided into therapy group and control group, 12 mice in each group. Thalidomide dissolved in 0.5% sodium carboxyl methyl cellulose (CMC) suspension was administered intraperitoneally once a day at the dose of 200 mg/kg in therapy group, and an equivalent volume of 0.5% CMC in control group. Mice were sacrificed on the 30th d, tumor size and weight and metastases in liver and lungs were measured. CD34 and VEGF mRNA in tumor tissue were detected by immunohistochemistry and semi-quantitative RT-PCR respectively and microvessel density (MVD) was counted. Serum concentrations of TNF-alpha and ALT and AFP were also tested. RESULTS: MVD and VEGF mRNA in therapy group were less than those in control group (31.08+/-16.23 vessels/HP vs 80.00+/-26.27 vessels/HP, 0.0538+/-0.0165 vs 0.7373+/-0.1297, respectively, P<0.05). No statistical difference was observed in tumor size and weight and metastases in liver and lungs. TNF-alpha was significantly lower in therapy group than in control group (28.64+/-4.64 ng/L vs 42.69+/-6.99 ng/L, P<0.05). No statistical difference in ALT and AFP was observed between groups. CONCLUSION:Thalidomide can significantly inhibit angiogenesis and metastasis of hepatocellular carcinoma. It also has inhibitory effects on circulating TNF-alpha.
Authors: R Yamaguchi; H Yano; Y Nakashima; S Ogasawara; K Higaki; J Akiba; D J Hicklin; M Kojiro Journal: Oncol Rep Date: 2000 Jul-Aug Impact factor: 3.906
Authors: E E Powell; C J Edwards-Smith; J L Hay; A D Clouston; D H Crawford; C Shorthouse; D M Purdie; J R Jonsson Journal: Hepatology Date: 2000-04 Impact factor: 17.425
Authors: J E Tseng; B S Glisson; F R Khuri; D M Shin; J N Myers; A K El-Naggar; J S Roach; L E Ginsberg; P F Thall; X Wang; S Teddy; K N Lawhorn; R E Zentgraf; G D Steinhaus; J M Pluda; J L Abbruzzese; W K Hong; R S Herbst Journal: Cancer Date: 2001-11-01 Impact factor: 6.860
Authors: T Santos-Mendoza; L Favila-Castillo; A Oltra; J Tamaríz; F Labarrios; S Estrada-Parra; L Estrada-García Journal: Int Arch Allergy Immunol Date: 1996-09 Impact factor: 2.749